Potential cost to patient safety as New Zealand debates access to medicinal cannabis

CLINICAL COMMENT

Michelle Glass and John Ashton from the University of Otago discuss whether untested cannabis-based products should enter the New Zealand healthcare system, as proposed by the Government’s recent consultation document